Scleroderma and related conditions (Q41333515)

29 September 2017

1 reference

title

Scleroderma and related conditions (English)

1 reference

29 September 2017

Mitchell H

1

1 reference

29 September 2017

Bolster MB

series ordinal

2

1 reference

29 September 2017

LeRoy EC

series ordinal

3

1 reference

29 September 2017

publication date

1 January 1997

1 reference

Medical Clinics of North America

29 September 2017

published in

1 reference

29 September 2017

volume

81

1 reference

29 September 2017

issue

1

1 reference

29 September 2017

page(s)

129-149

1 reference

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Predictors of survival in systemic sclerosis (scleroderma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

7 January 2021

Scleroderma in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

The articular manifestations of progressive systemic sclerosis (scleroderma).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

7 January 2021

Survival in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: A clinicopathologic study of 9 patients with progressive systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Serological markers in progressive systemic sclerosis: clinical correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Muscle disease in progressive systemic sclerosis. diagnostic and therapeutic considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Small intestinal bacterial growth in systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Motor disorders of the esophagus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Features of systemic sclerosis (scleroderma) in an identical twin pair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

The prognosis of localized scleroderma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Progressive systemic sclerosis in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Internal involvement in localized scleroderma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Scleroderma and the kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

The cardiovascular manifestations of systemic sclerosis (scleroderma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

The CREST syndrome: a distinct serologic entity with anticentromere antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Pneumatosis cystoides intestinalis associated with progressive systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Normotensive renal failure in systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Persistent effect of TGF-β1 on extracellular matrix gene expression in human dermal fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: insensitivity to TGF beta 1 stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Scleroderma after cosmetic surgery: four cases of human adjuvant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic associations in systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Single lung transplantation in patients with systemic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Dietary intake and nutritional status in patients with systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Epidemiology of fatal systemic sclerosis (diffuse scleroderma). A 15-year survey in Baltimore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Altered regulation of collagen metabolism in scleroderma fibroblasts grown within three-dimensional collagen gels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Nodular regenerative hyperplasia of the liver, CREST syndrome and primary biliary cirrhosis: an overlap syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Epidemiology of Systemic Sclerosis (Scleroderma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Survival with scleroderma—II: A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Skeletal muscle involvement in progressive systemic sclerosis (scleroderma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Lung disease associated with progressive systemic sclerosis. Assessment of interlobar variation by bronchoalveolar lavage and comparison with noninvasive evaluation of disease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Autoantibody to centromere (kinetochore) in scleroderma sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Scleroderma and primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Sequential dermal microvascular and perivascular changes in the development of scleroderma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

An Historical Account of the Study of Progressive Systemic Sclerosis (Diffuse Scleroderma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Silicone breast implants and rheumatic disease. Clinical, immunologic, and epidemiologic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Evaluation and management of scleroderma lung disease using bronchoalveolar lavage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

The toxicity of D-penicillamine in systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Factors predicting development of renal involvement in progressive systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Systemic scleroderma, A clinical study of 727 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Post-mammoplasty connective tissue disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970508-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(05)70508-3

1 reference

29 September 2017

1 reference